Man Group
RIGL icon

Man Group’s Rigel Pharmaceuticals RIGL Stock Holding History

Man Group’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$814K Sell
20,796
-57,225
-73% -$1.76M ﹤0.01% 1921
2026
Q1 		$2.11M Buy
78,021
+21,333
+38% +$717K ﹤0.01% 1555
2025
Q4 		$2.43M Buy
56,688
+33,853
+148% +$1.28M ﹤0.01% 1386
2025
Q3 		$647K Buy
22,835
+11,063
+94% +$331K ﹤0.01% 1791
2025
Q2 		$220K Buy
11,772
+1,501
+15% +$28.5K ﹤0.01% 2047
2025
Q1 		$185K Sell
10,271
-7,885
-43% -$160K ﹤0.01% 2040
2024
Q4 		$305K Sell
18,156
-7,442
-29% -$143K ﹤0.01% 1782
2024
Q3 		$414K Buy
25,598
+149
+0.6% +$1.75K ﹤0.01% 1700
2024
Q2 		$209K Buy
25,449
+13,349
+110% +$140K ﹤0.01% 1881
2024
Q1 		$179K Buy
+12,100
New +$163K ﹤0.01% 2023
2023
Q1 		– Sell
-13,011
Closed -$207K – 1813
2022
Q4 		$195K Buy
13,011
+10,465
+411% +$95.9K ﹤0.01% 1776
2022
Q3 		$30K Buy
+2,546
New +$34.4K ﹤0.01% 1919
2019
Q4 		– Sell
-1,100
Closed -$21K – 1892
2019
Q3 		$21K Buy
+1,100
New +$22.7K ﹤0.01% 1762
2018
Q3 		– Sell
-4,400
Closed -$125K – 2202
2018
Q2 		$125K Buy
+4,400
New +$157K ﹤0.01% 2062

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Man Group's RIGL Position: Q2 2026 in Review

Man Group reduced its Rigel Pharmaceuticals (RIGL) stake by 73% in Q2 2026, selling an estimated $1.76M and leaving 20,796 shares worth $814K. The position accounts for ﹤0.01% of the portfolio, ranked #1921.

Man Group first reported a position in RIGL in Q2 2018 and has held it in 14 quarters since. The position peaked at $2.43M in Q4 2025. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Man Group held 20,796 shares of Rigel Pharmaceuticals worth $814K as of Q2 2026.
  • Man Group sold 57,225 Rigel Pharmaceuticals shares in Q2 2026, an estimated $1.76M.
  • Rigel Pharmaceuticals made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #1921 holding.
  • Man Group first reported a position in Rigel Pharmaceuticals in Q2 2018 and has held it in 14 quarters since.
  • Man Group's Rigel Pharmaceuticals position peaked at $2.43M in Q4 2025.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.